341 related articles for article (PubMed ID: 17979703)
1. Antiangiogenic agents: an update on small molecule VEGFR inhibitors.
Schenone S; Bondavalli F; Botta M
Curr Med Chem; 2007; 14(23):2495-516. PubMed ID: 17979703
[TBL] [Abstract][Full Text] [Related]
2. Vascular endothelial cell growth factor (VEGF), an emerging target for cancer chemotherapy.
Shinkaruk S; Bayle M; Laïn G; Déléris G
Curr Med Chem Anticancer Agents; 2003 Mar; 3(2):95-117. PubMed ID: 12678905
[TBL] [Abstract][Full Text] [Related]
3. Recent advances in antiangiogenic agents with VEGFR as target.
Zhang J; Shan Y; Pan X; He L
Mini Rev Med Chem; 2011 Oct; 11(11):920-46. PubMed ID: 21762098
[TBL] [Abstract][Full Text] [Related]
4. Vascular endothelial growth factor (VEGF), VEGF receptors and their inhibitors for antiangiogenic tumor therapy.
Takahashi S
Biol Pharm Bull; 2011; 34(12):1785-8. PubMed ID: 22130231
[TBL] [Abstract][Full Text] [Related]
5. [VEGF-receptor inhibitors for anti-angiogenesis].
Shibuya M
Nihon Yakurigaku Zasshi; 2003 Dec; 122(6):498-503. PubMed ID: 14639004
[TBL] [Abstract][Full Text] [Related]
6. Targeting Angiogenesis in Cancer Therapy: Moving Beyond Vascular Endothelial Growth Factor.
Zhao Y; Adjei AA
Oncologist; 2015 Jun; 20(6):660-73. PubMed ID: 26001391
[TBL] [Abstract][Full Text] [Related]
7. Development of vascular endothelial growth factor receptor (VEGFR) kinase inhibitors as anti-angiogenic agents in cancer therapy.
Underiner TL; Ruggeri B; Gingrich DE
Curr Med Chem; 2004 Mar; 11(6):731-45. PubMed ID: 15032727
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of vascular endothelial growth factor-associated tyrosine kinase activity with SU5416 blocks sprouting in the microvascular endothelial cell spheroid model of angiogenesis.
Haspel HC; Scicli GM; McMahon G; Scicli AG
Microvasc Res; 2002 May; 63(3):304-15. PubMed ID: 11969307
[TBL] [Abstract][Full Text] [Related]
9. Antiangiogenic mechanisms of PJ-8, a novel inhibitor of vascular endothelial growth factor receptor signaling.
Huang SW; Lien JC; Kuo SC; Huang TF
Carcinogenesis; 2012 May; 33(5):1022-30. PubMed ID: 22436611
[TBL] [Abstract][Full Text] [Related]
10. VEGF signal system: the application of antiangiogenesis.
Liang X; Xu F; Li X; Ma C; Zhang Y; Xu W
Curr Med Chem; 2014 Mar; 21(7):894-910. PubMed ID: 24059233
[TBL] [Abstract][Full Text] [Related]
11. VEGF/VEGFR signalling as a target for inhibiting angiogenesis.
Kiselyov A; Balakin KV; Tkachenko SE
Expert Opin Investig Drugs; 2007 Jan; 16(1):83-107. PubMed ID: 17155856
[TBL] [Abstract][Full Text] [Related]
12. Vascular endothelial growth factor (VEGF) - key factor in normal and pathological angiogenesis.
Melincovici CS; Boşca AB; Şuşman S; Mărginean M; Mihu C; Istrate M; Moldovan IM; Roman AL; Mihu CM
Rom J Morphol Embryol; 2018; 59(2):455-467. PubMed ID: 30173249
[TBL] [Abstract][Full Text] [Related]
13. Selective VEGFR inhibitors for anticancer therapeutics in clinical use and clinical trials.
Zhang C; Tan C; Ding H; Xin T; Jiang Y
Curr Pharm Des; 2012; 18(20):2921-35. PubMed ID: 22571661
[TBL] [Abstract][Full Text] [Related]
14. VEGF/VEGFR pathway inhibitors as anti-angiogenic agents: present and future.
Sharma PS; Sharma R; Tyagi T
Curr Cancer Drug Targets; 2011 Jun; 11(5):624-53. PubMed ID: 21486218
[TBL] [Abstract][Full Text] [Related]
15. Angiogenesis inhibitors: a rational strategy for radiosensitization in the treatment of non-small-cell lung cancer?
Raben D; Helfrich B
Clin Lung Cancer; 2004 Jul; 6(1):48-57. PubMed ID: 15310417
[TBL] [Abstract][Full Text] [Related]
16. Expression of vascular endothelial growth factor (VEGF) and VEGF receptors in tumor angiogenesis and malignancies.
Pradeep CR; Sunila ES; Kuttan G
Integr Cancer Ther; 2005 Dec; 4(4):315-21. PubMed ID: 16282508
[TBL] [Abstract][Full Text] [Related]
17. Blocking VEGFR-3 suppresses angiogenic sprouting and vascular network formation.
Tammela T; Zarkada G; Wallgard E; Murtomäki A; Suchting S; Wirzenius M; Waltari M; Hellström M; Schomber T; Peltonen R; Freitas C; Duarte A; Isoniemi H; Laakkonen P; Christofori G; Ylä-Herttuala S; Shibuya M; Pytowski B; Eichmann A; Betsholtz C; Alitalo K
Nature; 2008 Jul; 454(7204):656-60. PubMed ID: 18594512
[TBL] [Abstract][Full Text] [Related]
18. Vascular endothelial growth factor and vascular endothelial growth factor receptor inhibitors as anti-angiogenic agents in cancer therapy.
Veeravagu A; Hsu AR; Cai W; Hou LC; Tse VC; Chen X
Recent Pat Anticancer Drug Discov; 2007 Jan; 2(1):59-71. PubMed ID: 18221053
[TBL] [Abstract][Full Text] [Related]
19. Vascular endothelial growth factor and its receptor system: physiological functions in angiogenesis and pathological roles in various diseases.
Shibuya M
J Biochem; 2013 Jan; 153(1):13-9. PubMed ID: 23172303
[TBL] [Abstract][Full Text] [Related]
20. The tyrosine kinase inhibitor cediranib blocks ligand-induced vascular endothelial growth factor receptor-3 activity and lymphangiogenesis.
Heckman CA; Holopainen T; Wirzenius M; Keskitalo S; Jeltsch M; Ylä-Herttuala S; Wedge SR; Jürgensmeier JM; Alitalo K
Cancer Res; 2008 Jun; 68(12):4754-62. PubMed ID: 18559522
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
